Notch signalling is a central regulator of differentiation in a variety of organisms and tissue types 1 . Its activity is controlled by the multisubunit c-secretase (cSE) complex 2 . Although Notch signalling can play both oncogenic and tumour-suppressor roles in solid tumours, in the haematopoietic system it is exclusively oncogenic, notably in T-cell acute lymphoblastic leukaemia, a disease characterized by Notch1-activating mutations 3 . Here we identify novel somaticinactivating Notch pathway mutations in a fraction of patients with chronic myelomonocytic leukaemia (CMML). Inactivation of Notch signalling in mouse haematopoietic stem cells (HSCs) results in an aberrant accumulation of granulocyte/monocyte progenitors (GMPs), extramedullary haematopoieisis and the induction of CMML-like disease. Transcriptome analysis revealed that Notch signalling regulates an extensive myelomonocytic-specific gene signature, through the direct suppression of gene transcription by the Notch target Hes1. Our studies identify a novel role for Notch signalling during early haematopoietic stem cell differentiation and suggest that the Notch pathway can play both tumour-promoting and -suppressive roles within the same tissue.
Notch is essential for the emergence of definitive haematopoiesis 4 , controls HSC differentiation to the T-cell lineage 5, 6 and is a major oncogene, as most patients with T-cell acute lymphoblastic leukaemia harbour activating Notch1 mutations 7 . To study haematopoiesis in the absence of any Notch-derived signal (as mammals express four different Notch receptors), we targeted Nicastrin (Ncstn), a member of the cSE complex and one of the few non-redundant members of the pathway ( Supplementary Fig. 1 ). We crossed the Ncstn f/f mice to both an inducible (Mx1-cre) 8 and a haematopoietic-specific (Vav-cre) 9 recombinase strain. Both modes of deletion (referred to herein as Ncstn 2/2 ) produced identical phenotypes. Unexpectedly, none of the Ncstn 2/2 mice survived longer than 20 weeks. Further analysis revealed a striking peripheral blood leukocytosis and monocytosis with enlargement of the spleen (Fig. 1a, b and Supplementary Figs 2 and 3 ). Histological analysis of the spleen showed a marked expansion of the red pulp with diffuse infiltration by myeloid and monocytic cells. The infiltrating myeloid cells were partly myeloperoxidase positive and CD11b 1 and/or Gr1 1 ( Fig. 1b and Supplementary Figs 2 and 3 ). The increase in monocyte numbers was also observed in the bone marrow and liver ( Fig. 1a and data not shown). Taken together, these findings were diagnostic for a myeloproliferative/myelodysplastic process and reminiscent of human CMML. CMML is a myeloid malignancy, classified as a myeloproliferative disorder/myelodysplastic syndrome overlap, which is characterized by monocytosis, myeloproliferation, variable bone marrow dysplasia and a high rate of progression to acute myeloid leukaemia 10 .
Because monocytes and granulocytes originate from the GMP subset, we examined the stem and progenitor cell populations in the bone marrow. Ncstn deletion lead to an enlargement of the Lineage neg Sca1 1 c-Kit 1 (LSK), specifically the LSK CD150 1 CD48 1 subset, a population shown to have a myeloid commitment bias 11 . This differentiation bias was coupled to a significant reduction of the lymphoid-biased multipotential progenitor population (L-MPP) 12 ( Supplementary Fig. 4 ). Moreover, there was a striking increase in the absolute numbers of both bone marrow and spleen GMP cells ( Fig. 1d ) coupled to a decrease of the megakaryocyte-erythrocyte progenitor population. This apparent predisposition towards GMP-derived lineages was also evident in vitro, as Ncstn 2/2 progenitors generated more granulocyte-macrophage and macrophage colonies ( Supplementary Fig. 5 ). Further studies also revealed a striking ability of the Ncstn 2/2 progenitors to replate serially ( Supplementary  Fig. 6 ), suggesting an increase in their self-renewal potential. Consistent with this idea, whole transcriptome profiling of Ncstn 2/2 GMP progenitors revealed enrichment of a 'leukemic self-renewal' signature 13 . Finally, bone marrow transplantation assays demonstrated that the effects of Ncstn deletion were cell autonomous ( Supplementary Fig. 7 ) 14 .
Although the cSE complex has other substrates 2 , we focused on Notch signalling because of our finding that Ncstn deletion led to known Notch 2/2 phenotypes, including a block in T-cell differentiation ( Supplementary Fig. 8 ) 15 . To prove a connection to Notch signalling, we generated animals that conditionally lack the expression of three out of four Notch receptors (Mx1-cre 1 N1 f/f N2 f/f N3 2/2 ) 16 . Strikingly, triple Notch1/2/3 deletion copied the Ncstn 2/2 phenotypes ( Supplementary Fig. 9 ). Notch1-3 2/2 mice developed both CMMLlike symptoms, and significant enlargement of the GMP population. Notch3 expression was dispensable, as simultaneous deletion of only Notch1 and Notch2 led to an identical CMML-like pathology. However, introduction of a single wild-type (WT) Notch1 or Notch2 allele was able to suppress the disease phenotype. Consistent with the importance of Notch1-2 receptor signalling in these stages, quantitative PCR studies revealed expression of Notch1 and Notch2, but not Notch3, in WT stem and progenitor cells ( Supplementary Fig. 10 ).
We next sought to delineate the mechanism by which Notch directs the regulation of early haematopoiesis. Deletion of Ncstn did not lead to any alterations in the GMP cell-cycle status or cell death rate (not shown). We hypothesized that cSE complex/Notch signals actively suppress a GMP-specific gene expression program. We sorted LSK and GMP cells and studied their transcriptome. This analysis revealed a statistically significant de-repression of an extended myeloid-specific program 12 in Ncstn 2/2 LSK cells ( Fig. 2a and Supplementary Fig. 11 ).
Gene-set enrichment analysis demonstrated a significant enrichment of myeloid-specific gene-sets within the Ncstn 2/2 LSK gene signature ( Fig. 2b and Supplementary Table 1 ). Further dissection of the LSK subset showed that the GMP gene expression program was initiated as early as the CD150 1 HSC stage of differentiation, and persisted at the CD150 2 subset, which included MPPs ( Supplementary Fig. 11 ). Furthermore, we were able to show that gene expression in LSKs purified from an inducible Notch1 gain-of-function genetic model (Ef1a1-lsl-Notch1 IC Mx1-cre 1 ) 17 was inversely correlated with the loss-of-function signature seen in Ncstn 2/2 LSK progenitors ( Fig. 2a ). Notch1 IC expression led to suppression of myeloid-specific genes, suggesting that activation of Notch signalling can alter the transcription and differentiation of uncommitted HSC and MPP cells. Gene-set enrichment analysis further supported these findings as it showed a negative correlation between the Notch1 IC LSKs and previously reported myeloid gene expression signatures ( Fig. 2a , b, Supplementary Table 2 and Supplementary Fig. 11 ).
As Notch is thought to function primarily as a transcriptional activator, we hypothesized that its suppressive effects on GMP-specific gene expression could be explained by the induction of a transcriptional repressor. A search for such a molecule revealed Hes1, a known Notch target and a transcriptional repressor ( Supplementary Fig. 11a ). Interestingly, Hes1 was previously suggested to play a role in myeloid leukaemia, as a downstream effector of the Junb tumour suppressor in an animal model of chronic myeloid leukemia 18 . To test the potential involvement of Hes1 directly, we used in vitro differentiation assays and showed that Hes1 ectopic expression was sufficient to direct differentiation away from the granulocyte/monocyte lineage ( Fig. 2c ). Furthermore, Hes1 expression suppressed the expression of key granulocyte/monocyte commitment genes such as Cebpa and Pu.1 ( Supplementary Fig. 12a ). In agreement with this finding, we identified putative Hes (N-box) binding sites on the promoters of both genes. Reporter and chromatin immunoprecipitation assays proved direct binding of Hes1 on these promoters and suppression of transcription ( Supplementary Fig. 12b-e ).
These findings suggested that Notch (or Hes1) hyper-activation could suppress CMML-like disease developing in Ncstn 2/2 animals. To test this, we used the previously described Ef1a1-lsl-Notch1 IC1 mice 17 . We generated Notch1 IC Ncstn f/f2 Mx1-Cre 1 animals and analysed both GMP accumulation and disease progression. Notch1 IC expression was LETTER RESEARCH sufficient to suppress both GMP expansion and disease development significantly (Fig. 3a, b and Supplementary Fig. 13 ). Interestingly, Notch1 IC expression drove progenitor commitment towards the lymphoid (T cell) and megakaryocyte-erythrocyte progenitor lineages 19 . However, Notch1 IC expression did not affect cell-cycle kinetics within the GMP subset ( Supplementary Fig. 13 ). To uncouple differentiation to the GMP subset from effects on GMP homeostasis, we purified WT GMP and plated them on stroma in the presence or absence of Notch ligands (Dll1 and Dll4). A striking increase of apoptosis rate was noted in the presence of Dll1-4 (Fig. 3c) . These experiments suggest that Notch ectopic expression can affect both the commitment to the GMP subset and the survival of already committed GMP progenitors.
Our studies so far demonstrate that Notch controls murine myelopoiesis and that its deletion leads to GMP expansion and monocytic disease. To prove that Notch is also important in human haematopoiesis and leukemogenesis, we initially cultured purified human CD34 1 CD38 2 Lin 2 bone marrow and cord blood stem and progenitor cells on stroma expressing different Jagged and Delta-like Notch ligands 20 . We found that expression of Notch ligands efficiently suppressed differentiation of human multipotential progenitors towards both the granulocyte (CD15 1 ) and monocyte (CD14 1 ) lineages ( Supplementary Figs 14 and 15 ). This suppression was prevented when the activity of the cSE complex was suppressed using either small molecule inhibitors or by the expression of a dominant negative MAML1 mutant.
To gain further insights into the role of Notch in human CMML, we extensively sequenced many cSE/Notch pathway genes. Exon resequencing of specimens from patients with CMML (Supplementary Table 3 ) identified a substantial fraction (six novel mutations in 5 out of 42 patients) harbouring somatic heterozygous mutations in multiple Notch pathway genes including NCSTN, APH1, MAML1 and NOTCH2 ( Fig. 4 and Supplementary Table 4 ). In addition, several other putative mutations (single nucleotide variants) were detected, which are not annotated as known germline single nucleotide polymorphisms but for which we could not prove a somatic origin (Supplementary Table 5 ). The validated somatic mutations were only observed in CMML, as re-sequencing of 47 samples from patients with myeloproliferative disorders (polycythemia vera or myelofibrosis) did not reveal somatic mutations in the Notch pathway (Fig. 4b) . Importantly, CMML specimens with Notch mutations also had somatic alterations in well-characterized myeloid oncogenic lesions 21 , CMML. a, Sequence traces of identified Notch pathway mutations in tumours from patients with CMML but not in normal tissues show somatic origin. b, Comparison of the percentage of Notch pathway mutations in specimens from patients with CMML, myelofibrosis and polycythemia vera. The asterisk denotes that only verified somatic CMML mutations are included. c, OP9-DL1 co-culture of WT LSK cells infected with specified constructs. Analysis of the CD11b 1 population was studied 14 days after the initiation of the culture. d, A similar experiment as in c, using LSK Ncstn 2/2 progenitors infected with the specified constructs. In all cases, a representative of more than three experiments is shown.
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including JAK2, KRAS, TET2 and ASXL1, suggesting mutational cooperation between Notch signalling and other oncogenic pathways in CMML ( Supplementary Table 4 ). We then asked if those mutations were causally related with the disease by using transcriptional reporter and in vitro differentiation assays. We demonstrated that selected mutations had the ability to affect Notch activity negatively either as dominant negative (MAML1Q345X) or null (NCSTNA433T) alleles (Fig. 4c, d and Supplementary Fig. 16 ). This is the first description, to our knowledge, of somatic Notch pathway loss-of-function mutations in human cancer.
The presented studies identify novel inactivating Notch pathway mutations and suggest that cSE complex/Notch signalling controls early HSC/MPP commitment decisions in bone marrow. A significant portion of this regulation is controlled by the Hes family of transcriptional repressors. Most importantly, our studies suggest that silencing Notch activity leads to the development of myeloid leukaemia, implying a novel tumour-suppressor function for the Notch pathway in haematopoiesis. Although mutation-mediated pathway silencing can be found in CMML, it is conceivable that there are additional control mechanisms, including epigenetic silencing of Notch pathway target genes. Whatever the mode of regulation, our observations suggest that reversible activation of the Notch pathway may represent an attractive future therapy, targeting specifically the progression and relapse of granulocytic and monocytic neoplasms.
METHODS SUMMARY
Animals. All mice were kept in specific pathogen-free animal facilities at the New York University School of Medicine. Mx1-Cre 1 animals were injected with 20 mg polyI:polyC per gram of body weight for a total of six injections. The injections were initiated 14 days after birth and done every 2 days. Animals were analysed 4-6 weeks after the last injection unless indicated otherwise. All animal experiments were done in accordance to the guidelines of the New York University School of Medicine Institutional Animal Care and Use Committee. Antibodies and fluorescence-activated cell sorting analysis. Antibody staining and fluorescence-activated cell sorting (FACS) were performed as previously described 22 . All antibodies were purchased from BD-Pharmingen or e-Bioscience. We used the following antibodies: c-kit (2B8), Sca-1 (D7), Mac-1 (M1/70), Gr-1 (RB6-8C5), NK1.1 (PK136), TER-119, CD3 (145-2C11), CD19 (1D3), IL7Ra (A7R34), CD34 (RAM34), FccRII/III (2.4G2), Flk-2/Flt-3 (A2F10.1), CD4 (RM4-5), CD4 (H129.19), CD8 (53-6.7), CD45.1 (A20), CD45.2 (104), CD150 (9D1), CD48 (HM481). Bone marrow lineage antibody cocktail included Mac-1, Gr-1, NK1.1, TER-119, CD3 and CD19. OP9-DL1/DL4 in vitro co-culture. OP9-DL1/DL4 cells were maintained in MEM with 20% fetal bovine serum. Ten thousand purified infected (green fluorescent protein (GFP 1 )) LSK or cKit 1 bone marrow progenitors were seeded into a six-well plate with confluent OP9 cells in the presence of 10 ng ml 21 SCF, 10 ng ml 21 interleukin-3 (IL-3), 5 ng ml 21 Flt3-L, 10 ng ml 21 IL6 and 5 ng ml 21 IL-7. Flow cytometric analysis was performed on an LSRII (BDIS). Haematopoietic cells were gated using CD45 cell-surface expression. Microarray analysis. LSK or GMP cells from individual mice were used. To generate sufficient sample quantities for oligonucleotide gene chip hybridization, we used the Ovation RNA Amplification System V2 (Nugen) for antisense RNA (cRNA) amplification and labelling. The amplified cRNA was labelled and hybridized to the Mouse 430.2 microarrays (Affymetrix). The data were normalized using the previously published robust multi-array average algorithm using the GeneSpring GX software (Agilent).
